First-in-class peptide and monoclonal antibody therapeutics for obesity.
OB-Atlas–driven discovery advancing OB001 and OB002, the first programs in our OB-Series pipeline for obesity and its complications.
SNAPSHOT
OBPharm at a glance
Responses typically within 48 hours
*Preclinical findings; not yet evaluated in humans.
STRUCTURE VIEW
Physics-informed design for CKM therapeutics
OBPharm takes a first-principles, physics‑informed approach to cardiometabolic and CKM disease—connecting sequence to structure to function and translating that logic into engineered peptides and monoclonal antibodies.
Representative structure for illustration. Program-specific structures, figures, and protocols are available for qualified partners under CDA.
PLATFORM
Atlas-guided discovery for obesity and cardiometabolic-renal disease.
CAPABILITIES
- Multimodal biomarker & phenotype modeling
- Target prioritization & translational rationale
- Peptide & monoclonal antibody lead optimization
Discovery to Translation
From biomarkers to target selection, lead optimization, and translational rationale.
Preclinical differentiation
Focus on metabolic and inflammatory mechanisms with lean-mass preserving profiles (preclinical).
Partner-ready
Designed for licensing, co-development, and strategic collaborations.
AI PLATFORM
Built around the OB-platform of foundation models.
OB-Atlas models disease biology, OB-Design generates candidates, and OB-Translate drives closed-loop validation—compressing discovery-to-clinic cycles across the OB-Series.
OB-Atlas-Peptide
Multimodal foundation model for peptide therapeutics, integrating sequence, structure, and biomarker context to prioritize peptide candidates with differentiated efficacy and developability profiles.
OB-Atlas-mAb
Structure- and epitope-aware foundation model for monoclonal antibodies, combining biomarker stratification, target biology, and developability constraints to guide antibody discovery and optimization.
OB-Atlas-CKM
Cardiometabolic foundation model integrating biomarkers, molecular features, and phenotypic data to model disease progression and therapeutic response across obesity and CKM indications.
PIPELINE
Programs advancing toward the clinic.
Our OB-Series pipeline is led by OB001 and OB002, with additional peptide and monoclonal antibody programs in development.
Lead OB-Series program with differentiated preclinical profile and strong translational rationale.
Follow-on OB-Series program targeting cardiometabolic complications, supported by biomarker-driven discovery.
Additional peptide and monoclonal antibody programs in development across obesity and CKM complications.
Partner with OBPharm
Reach out for partnering discussions, scientific questions, or to request the latest deck.